75 State Street
Boston, MA 02109
617 349 1971
Impiegati a tempo pieno: 45
|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Ms. Jill C. Milne Ph.D.||Co-Founder, CEO, Pres & Director||928,52k||N/D||1968|
|Mr. Benjamin S. Harshbarger J.D.||Chief Legal Officer||621,91k||N/D||1969|
|Mr. Noah Clauser CPA||CFO & Treasurer||N/D||N/D||1974|
|Ms. Keri McGrail||Sr. VP of HR||N/D||N/D||N/D|
|Ms. Andrea L. Matthews||Chief Bus. Officer||N/D||N/D||N/D|
|Mr. Andrew A. Komjathy||Chief Commercial Officer||N/D||N/D||1964|
|Dr. Anthony Christopher Stevens M.D.||Interim Chief Medical Officer||N/D||N/D||1959|
|Dr. Christopher J. Morabito M.D.||Chief Medical Officer||N/D||N/D||1970|
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
L'ISS Governance QualityScore di Astria Therapeutics, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.